Table 4.
Lymphocytes population expressed in concentration and percentage of total lymphocytes in 23 patients affected by Adenoviral AURTIs during the febrile (acute) and afebrile (convalescence) phases, p values reflect difference in means.
| Test | Acute Phase | CI or IR | Convalescence | CI or IR | p |
|---|---|---|---|---|---|
| Total lymphocytes (/µL) | 5159 | 3916–6402 | 4898 | 4053–5743 | 0.66 |
| (%) | 34.6% | 28.9–40.2% | 60.1% | 54.8–66.4% | 0.00 |
| Natural killer (/µL) | 414 | 235–562 * | 385 | 234–536 | 0.6782 |
| (%) | 9.9% | 7.3–12.5% | 6.6% | 4.2–9% | 0.3281 |
| B lymphocytes (/µL) | 782 | 439–1125 | 754 | 555–953 | 0.011 |
| (%) | 25.1% | 19.3–31.8% | 15.3% | 11.6–19% | 0.021 |
| T lymphocytes (/µL) | 2455 | 1482–3939 * | 2788 | 2099–3478 | 0.07 |
| (%) | 57.4% | 43.2–71.6% | 58.3% | 44.7–60% * | 0.77 |
| T Helper (T CD4+) (/µL) | 1159 | 675–1643 | 1831 | 1282–2381 | 0.071 |
| (%) | 40.15% | 31.7–48.6% | 33.4% | 25.1–42% | 0.391 |
| T CD4+ naïve (/µL) | 1513 | 1037–1989 | 845 | 450–1259 | 0.181 |
| (%) | 29.4% | 23.4–35.1% | 29% | 23.8–34.2% | 0.911 |
| T CD4+ memory (/µL) | 313 | 231–416 * | 272 | 232–457 * | 0.962 |
| (%) | 6.3% | 5.1–0.3% | 7.2% | 5.6–8.4% | 0.62 |
| T Cytotoxic (T CD8+) (/µL) | 594 | 433–1054 | 1241 | 638–1.844 | 0.572 |
| (%) | 14.8% | 9–26.5% | 16.3% | 13.2–19.4% | 0.682 |
| T CD8+ naïve (/µL) | 476 | 343–811 | 560 | 369–751 | 0.652 |
| (%) | 14.3% | 8.8–19.7% | 12.3% | 9.7–13.2% * | 0.772 |
| T CD8+ memory (/µL) | 78 | 48–132 * | 148 | 86–211 | 0.662 |
| (%) | 2.6% | 1.3–4% | 3.2% | 2–4.5% | 0.651 |
| T regulatory (/µL) | 2152 | 1763–2540 | 2471 | 2258–3120 * | 0.042 |
| (%) | 65.8% | 36.1–75.6% * | 61.8% | 25.1–79.2% * | 0.515 |
* data not normally distributed.